Comparison of Dopamine and Norepinephrine in the Treatment of Shock
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0.19 microg per kilogram per minute for norepinephrine, open-label norepinephrine, epinephrine, or vasopressin could be added. The primary outcome was the rate of death at 28 days after randomization; secondary end points included the number of days without need for organ support and the occurrence of adverse events. RESULTS: The trial included 1679 patients, of whom 858 were assigned to dopamine and 821 to norepinephrine. The baseline characteristics of the groups were similar. There was no significant between-group difference in the rate of death at 28 days (52.5% in the dopamine group and 48.5% in the norepinephrine group; odds ratio with dopamine, 1.17; 95% confidence interval, 0.97 to 1.42; P=0.10). However, there were more arrhythmic events among the patients treated with dopamine than among those treated with norepinephrine (207 events [24.1%] vs. 102 events [12.4%], P<0.001). A subgroup analysis showed that dopamine, as compared with norepinephrine, was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock (P=0.03 for cardiogenic shock, P=0.19 for septic shock, and P=0.84 for hypovolemic shock, in Kaplan-Meier analyses). CONCLUSIONS: Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dopamine (DA) is a neurotransmitter in the catechol family, which is often used as first-line vasoactive drug in patients with septic shock (43).”
From Dopamine Is a Siderophore-Like Iron Chelator That Promotes Salmonella enterica Serovar Typhimurium Virulence in Mice (2019) · cites this paper as [43]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Self-citationWriting Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationCDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Current Epidemiology of Septic Shock: The CUB-Réa Network
Annane, D., Aegerter, P., Jars-Guincestre, M. C., & Guidet, B. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2201087 · Cited by 637
Research works printed but not linked: 1
- Mullner M, 2004, Cochrane Database Syst Rev, 3, CD003709
Cited by
Items 801–900 of 1,000
Lu, P., Sun, Y., Gong, X., Li, Z., & Hong, W. (2023) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2022-001804 · Cited by 13
Cardiac arrest, stony heart, and cardiopulmonary resuscitation: An updated revisit
El-Menyar, A. A., & Wahlen, B. M. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i3.126 · Cited by 13
Randhawa, V. K., Baran, D. A., Kanwar, M. K., Hernández-Montfort, J., Sinha, S. S., Barnett, C. F., & Billia, F. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.027 · Cited by 13
A neuroimmune pathway drives bacterial infection
Wang, N., Liu, J., Wu, R., Chen, F., Zhang, R., Yu, C., Zeh, H. J., Xiao, X., Wang, H., Billiar, T. R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2226 · Cited by 13
Is Mania the Hypertension of the Mood? Discussion of A Hypothesis
Rihmer, Z., Gonda, X., & Döme, P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160902145635 · Cited by 13
“Catecholamines play an important role in the regulation of blood pressure which is supported inter alia by the fact that dopamine and to a lesser extent noradrenaline are the most widely used and also the most effective rapidly acting drugs to increase the pathologically low blood pressure [25].”
BackgroundOptimum treatment of vasopressor-dependent distributive shock
Vincent, J., & Léone, M. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1252673 · Cited by 13
“vasopressors – norepinephrine is the vasopressor of choice [38,39] – and fluids are started simultaneously.”
BackgroundSelf-citationOptimal course of treatment in acute cardiogenic shock complicating myocardial infarction
Nuding, S., Werdan, K., & Prondzinsky, R. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1425141 · Cited by 13
“various etiologies) [88]: in the total population, norepinephrine showed a tendency to lower mortality than dopamine (28day mortality: 45.”
BackgroundAbril, M. K., Khanna, A. K., Kroll, S., McNamara, C., Handisides, D. R., & Busse, L. W. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.12.007 · Cited by 13
“In addition, there appears to be no demonstrable survival advantage for the use of any vasopressor over another [4,9,10].”
BackgroundInotropic agents in cardiogenic shock
Polyzogopoulou, E., Arfaras-Melainis, A., Bistola, V., & Parissis, J. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000744 · Cited by 13
“This characteristic of norepinephrine makes it a useful tool in the management of cardiogenic shock compared with other vasopressors, such as dopamine and epinephrine [40].”
BackgroundMehta, A., Khalid, A., & Swaroop, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86800 · Cited by 13
ST-Segment Elevation Myocardial Infarction
Enriquez, J. R., & de Lemos, J. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6705-2_26 · Cited by 13
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis
Cook, D. J., Protect Investigators, Canadian Critical Care Trials Group and the, Arabi, Y. M., Ferguson, N. D., Heels‐Ansdell, D., Freitag, A. P., McDonald, E., Clarke, F. J., Keenan, S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-3074-x · Cited by 13
Shock management in acute myocardial infarction
Pöss, J., Desch, S., & Thiele, H. (2014) · EuroIntervention · doi:10.4244/eijv10sta12 · Cited by 13
Blood transfusion practices in sepsis
Murthy, T. (2014) · Indian Journal of Anaesthesia · doi:10.4103/0019-5049.144676 · Cited by 13
“or who develop cardiogenic pulmonary oedema.[10,11]”
Gréau, E., Lascarrou, J.-B., Thuaut, A. L., Maquigneau, N., Alcourt, Y., Coutolleau, A., Rousseau, C., Erragne, V., & Reignier, J. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0083-7 · Cited by 13
“Norepinephrine chiefly induces vasoconstriction and is considered the vasopressor of choice for most critically ill patients with shock [1, 2, 20].”
BackgroundEffects of Chronic Antihypertensives on Vasopressor Dosing in Septic Shock
DeMott, J. M., Patel, G. P., & Lat, I. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017726552 · Cited by 13
“Total time on vasopressors differed between groups (median hours [IQR]: no β-blocker or ACE inhibitor, 30h [17-60]; β-blocker only, 24h [10-69]; ACE inhibitor only, 19h [6-25]; β-blocker and ACE inhibitor, 30h [15-58]; P = 0.”
BackgroundDavis, W. T., Montrief, T., Koyfman, A., & Long, B. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.04.047 · Cited by 13
“An RCT comparing dopamine and norepinephrine in shock found that dysrhythmias weremore common with the use of dopamine (24%) versus norepinephrine (12%) [71].”
BackgroundEarly May Be Better: Early Low-Dose Norepinephrine in Septic Shock
Russell, J. A., Gordon, A. C., & Walley, K. R. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201901-0083ed · Cited by 13
Survival prediction for heart failure complicated by sepsis: based on machine learning methods
Zhang, Q., Xu, L., He, W., Lai, X., & Huang, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1410702 · Cited by 12
JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis
Tamura, Y., Kusunose, K., Yamashita, Y., Akagi, T., Atsukawa, M., Fukumoto, Y., Goda, A., Goto, S., Hatano, M., Ikeda, M., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-1144 · Cited by 14
Li, C.-J., Wu, K.-H., Chen, C.-C., Law, Y., Chuang, P., & Chen, Y.-C. (2020) · Emergency Medicine International · doi:10.1155/2020/7951025 · Cited by 12
Zhu, B., Jiang, J., Yu, H., Huang, L. J., & Zhou, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-52514-5 · Cited by 12
First-Line Vasopressor and Mortality Rates in ED Patients with Acute Drug Overdose
Clifford, C., Sethi, M., Cox, D., & Manini, A. F. (2020) · Journal of Medical Toxicology · doi:10.1007/s13181-020-00797-1 · Cited by 12
Wu, C., Zhang, X., Xie, J., Li, Q., He, J., Hu, L., Wang, H., Liu, A., Xu, J., Yang, C., et al. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2031 · Cited by 12
Wood, A. J. T., Rauniyar, R., Jacques, A., Palmer, R. N., Wibrow, B. A., & Anstey, M. (2022) · Anaesthesia and Intensive Care · doi:10.1177/0310057x221105297 · Cited by 12
Dopamine versus noradrenaline in septic shock
Xu, B., & Peter, O. (2011) · Australasian Medical Journal · doi:10.4066/amj.2011.761 · Cited by 12
Adrenergic Effect on Cytokine Release After Ex Vivo Healthy Volunteers’ Whole Blood LPS Stimulation
Papandreou, V., Kavrochorianou, N., Katsoulas, T. A., Myrianthefs, P. M., Venetsanou, K., & Baltopoulos, G. J. (2016) · Inflammation · doi:10.1007/s10753-016-0338-y · Cited by 12
Approach to the Patient with Shock
Rivers, E. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00106-8 · Cited by 12
van Engelen, T. S. R., Wiersinga, W. J., & van der Poll, T. (2018) · Springer eBooks · doi:10.1007/978-3-319-73506-1_3 · Cited by 13
Peris, A., Lazzeri, C., D’Antonio, L., Bombardi, M., Bonizzoli, M., Guetti, C., Maccherini, M., & Migliaccio, M. L. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1897-8 · Cited by 12
A current appraisal of evidence for the approach to sepsis and septic shock
Varon, J., & Baron, R. M. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119856517 · Cited by 12
Zhou, D., Zhu, B., Jiang, J., Zhou, G., & Zhou, S. (2020) · Medical Science Monitor · doi:10.12659/msm.927716 · Cited by 12
Workgroup, S. N. T. T. M., Chia, Y. W., Lim, S. L., Loh, J., Leong, B. S., & Ong, M. E. H. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021115 · Cited by 12
Best vasopressor for advanced vasodilatory shock: should vasopressin be part of the mix?
Maybauer, M. O., & Walley, K. R. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-1942-1 · Cited by 12
“Clinical context may drive the choice of adrenergic agonist; for example, norepinephrine may be superior to dopamine when the potential for arrhythmias is of concern [6].”
BackgroundInfluentialTurck, C. J., Frazee, E., Kram, B., Daley, M. J., Day, S. A., Horner, D., Lesch, C. A., Mercer, J. M., Plewa-Rusiecki, A. M., & Herout, P. M. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130303 · Cited by 12
Graf, T., Desch, S., Eitel, I., & Thiele, H. (2015) · Coronary Artery Disease · doi:10.1097/mca.0000000000000259 · Cited by 12
Management of Acute Kidney Injury and Acid-Base Balance in the Septic Patient
Weyker, P. D., Pérez-Fernández, X. L., & Liu, K. D. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.01.012 · Cited by 12
Therapeutic Approach to the Critically Poisoned Patient
Schwarz, E. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_63-1 · Cited by 11
Carrier, F. M., Girard, M., Zuo, R. M., Ziegler, D., Trottier, H., & Chassé, M. (2023) · Transplantation · doi:10.1097/tp.0000000000004744 · Cited by 11
Should we initiate vasopressors earlier in patients with septic shock: A mini systemic review
Zhou, H.-X., Yang, C.-F., Wang, H.-Y., Teng, Y., & He, H. (2023) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v12.i4.204 · Cited by 11
Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis
Ma, D., Fang, W., Cai, L., Li, W., & Su, H. (2025) · Critical Care · doi:10.1186/s13054-025-05602-5 · Cited by 11
“Furthermore, we verified SIRT3 as a regulator of HO-1 For septic patients, norepinephrine is the first-line vasopressor used to guarantee stable blood pressure and organ perfusion [2].”
Vasoplegia from Continuous Flow Left Ventricular Assist Devices
Sathianathan, S., Bhat, G., & Dowling, R. D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01534-y · Cited by 11
Peranan Inotropik dan Vasopresor dalam Terapi Syok Kardiogenik
Pratama, A. R., & Fadil, M. (2021) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v48i6.78 · Cited by 11
Jackson, K. E., & Semler, M. W. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.05.003 · Cited by 11
Nakamura, S., Numata, G., Yamaguchi, T., Tokiwa, H., Higashikuni, Y., Nomura, S., Sasano, T., Takimoto, E., & Komuro, I. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.031 · Cited by 11
Eftychiou, S., Kalakoutas, A., & Proudfoot, A. G. (2022) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2022.10.002 · Cited by 11
“[41] De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al.”
BackgroundAdvanced heart failure: a contemporary approach
Chun, K., & Kang, S. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.159 · Cited by 11
Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis*
Smith, L. M., Mentz, G. B., & Engoren, M. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005975 · Cited by 11
Trzeciak, P., Stępińska, J., Gil, R. J., Hawranek, M., Nadolny, K., Tycińska, A., Bartuś, S., Gierlotka, M. J., Kałużna‐Oleksy, M., Zymliński, R., et al. (2023) · PubMed · doi:10.33963/v.kp.97817 · Cited by 11
“Patients in the dopamine group showed higher rates of arrhythmia and no significant reduction in mortality [37].”
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock
Mergoum, A. M., Rhone, A., Larson, N. J., Dries, D. J., Blondeau, B., & Rogers, F. B. (2024) · Journal of Intensive Care Medicine · doi:10.1177/08850666241246230 · Cited by 11
“26 In cardiogenic shock, the minimal β -adrenergic effect seen with norepinephrine is less likely to lead to arrhythmias or signi fi cant myocardial oxygen consumption.”
Recent trends in septic shock management: a narrative review of current evidence and recommendations
Nofal, M. A., Shitawi, J., Altarawneh, H. B., Alrosan, S., Alqaisi, Y., Al-Harazneh, A.-M., Alamaren, A. M., & Abu‐Jeyyab, M. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002048 · Cited by 11
“Due to its tendency to cause tachyarrhythmia and considerably decrease outcomes in this situation, dopamine usage is avoided in sepsis [33,34] .”
BackgroundOptimization of Pacing After Cardiopulmonary Bypass
Chua, J. H., Schwarzenberger, J. C., & Mahajan, A. (2011) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2011.07.005 · Cited by 11
Wuethrich, P. Y., & Burkhard, F. C. (2015) · Current Urology Reports · doi:10.1007/s11934-015-0490-1 · Cited by 11
Franco, E., Nuñez-Gil, I. J., Vivas, D., Mateos, B. R., Ibáñez, B., Gonzalo, N., Macaya, C., & Fernández‐Ortíz, A. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.07.009 · Cited by 11
“recently conducted a randomized trial [48] in which 1679 patients with shock were treated with either dopamine or norepinephrine.”
BackgroundCritical Care Cardiology Research: A Call to Action
van Diepen, S., Cook, D. J., Jacka, M. J., & Granger, C. B. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.969501 · Cited by 11
“In a trial evaluating pressor strategies (Sepsis Occurrence in Acutely Ill Patients II [SOAP II]), patients with cardiogenic shock receiving dopamine as a first-line vasopressor had a higher mortality than patients receiving norepinephrine; however, the unreported rate of many prognostically important cardiac variable…”
BackgroundGuo, S., Chen, Y., & Yu, X. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.205862 · Cited by 11
“7%).[2] The difference between our findings and those may relate to the different cohort.”
ResultAngiotensin II: A New Vasopressor for the Treatment of Distributive Shock
Allen, J. M., & Gilbert, B. W. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.09.014 · Cited by 11
Vasopressor Therapy and the Brain: Dark Side of the Moon
Heming, N., Mazeraud, A., Azabou, É., Moine, P., & Annane, D. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2019.00317 · Cited by 11
“The incidence of cardiac arrhythmia is greater with dopamine than with norepinephrine (125, 126).”
BackgroundCardiogenic shock: a major challenge for the clinical trialist
Sarma, D., Jentzer, J. C., & Soussi, S. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001066 · Cited by 11
“[56] (2010) SOAP-2 (N1⁄4280) CS Dopamine (n1⁄4135) is associated with a higher rate of 28-day mortality and arryhthmia than Norepinephrine (n1⁄4145) among the subset of patients with CS.”
BackgroundNuevas alternativas terapéuticas para la sepsis grave en el paciente crítico. Revisión
Loza-Vázquez, A., Gil, C. L., & Regidor, A. L. (2011) · Medicina Intensiva · doi:10.1016/j.medin.2010.10.002 · Cited by 11
Intra-Aortic Balloon Pump (IABP) in cardiogenic shock
Fuernau, G. F., & Thiele, H. (2013) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e328364d78d · Cited by 11
“The recently published Sepsis Occurrence in Acutely Ill Patients II (SOAP-II) trial found significant higher mortality rates with dopamine over norepinephrine as vasopressor in the cardiogenic shock subgroup [28].”
Vasopresores e inotrópicos: uso en pediatría
García-Canales, A., Peña-Juárez, R. A., & Sandoval-Franco, L. D. M. (2017) · Archivos de cardiología de México · doi:10.1016/j.acmx.2017.02.005 · Cited by 11
Passos, R. D. H., Ramos, J. G. R., Gobatto, A. L. N., Caldas, J. R., Macedo, E. M., & Batista, P. B. P. (2018) · Critical Care · doi:10.1186/s13054-018-2009-x · Cited by 11
Prescribing of Pressor Agents in Septic Shock: A Survey of Critical Care Pharmacists
Smith, S. E., Sikora, A. N., & Tackett, R. L. (2019) · Journal of Pharmacy Technology · doi:10.1177/8755122519846164 · Cited by 11
Advances in Vasodilatory Shock: A Concise Review
Thakur, S. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23266 · Cited by 11
“In Dopamine versus Norepinephrine trial (MC, RTC) no significant difference in 28 day, 6 month or 12 month mortality was recorded.[9] In meta-analysis of 32 trials of vasopressors in septic shock, norepinephrine was the most favoured agent (RR 0.”
Perioperative Management of Patients with Sepsis and Septic Shock, Part I
Bughrara, N. F., Cha, S., Safa, R., & Pustavoitau, A. (2020) · Anesthesiology Clinics · doi:10.1016/j.anclin.2019.10.013 · Cited by 12
Modern Vasopressor Therapy of Septic Shock (Review)
Kochkin, А. А., Yavorovskiy, A. G., Бондоевич, Б. Л., & Likhvantsev, V. V. (2020) · General Reanimatology · doi:10.15360/1813-9779-2020-2-77-93 · Cited by 11
“Использование этого препарата для «нефропротекции», как это рекомендовалось еще совсем недавно [45], сегодня признано неоправданным [2], так как нет убедительных доказательств его эффективности в отношении улучшения почечного кровотока, увеличения темпа диуреза и снижения потребности в заместительной почечной терапии…”
BackgroundInfluentialInotrope and Vasopressor Therapy of Septic Shock
Hollenberg, S. M. (2011) · Critical Care Nursing Clinics of North America · doi:10.1016/j.ccell.2010.12.008 · Cited by 11
Prise en charge du choc cardiogénique chez l’adulte
Lévy, B., Bastien, O. H., Bendjelid, K., Cariou, A., Chouihed, T., Combes, A., Mebazaa, A., Mégarbane, B., Plaisance, P. I., Ouattara, A., et al. (2014) · Réanimation · doi:10.1007/s13546-014-0915-8 · Cited by 11
“noradrénaline est utilisée en comparaison à la dopamine [12].”
Essential lessons in cardiogenic shock: Epinephrine versus norepinephrine/dobutamine*
Krenn, L., & Karth, G. D. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318208e381 · Cited by 11
Angiotensin II for the Treatment of Vasodilatory Shock — Promise and Caution
Dellinger, R. P., & Trzeciak, S. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706903 · Cited by 11
Use of vasopressors in patients with acute kidney injury on continuous kidney replacement therapy
Ramesh, A., Doddi, A., Abbasi, A., Al-Mamun, M. A., Sakhuja, A., & Shawwa, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0315643 · Cited by 10
Patel, S. M., Berg, D. D., Bohula, E. A., Palazzolo, M. G., Batchelor, W., Drakos, S. G., Kilic, A., Kormos, R. L., Samsky, M. D., Jessup, M. L., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044373 · Cited by 10
“13 With respect to inodilator therapy, the DOREMI (Dobutamine Compared with Milrinone) trial randomized 192 patients with CS to milrinone or dobutamine, finding no significant difference for a broad primary composite outcome that included all-cause mortality, resuscitated cardiac arrest, escalation…”
Hypertonic Saline in Human Sepsis: A Systematic Review of Randomized Controlled Trials
Orbegozo, D., Vincent, J., Créteur, J., & Su, F. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003955 · Cited by 10
Self-citationShock in China 2018 (SIC-study): a cross-sectional survey
Su, L., Ma, X., Xi, R., He, H., Wang, Y., Shan, G., Kang, Y., Shang, Y., Zheng, R., Li, S., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-310 · Cited by 10
“A clinical trial involving more than 1,600 patients with unexplained shock showed that the proportion of septic shock was approximately 62%; others included cardiogenic shock in 16% and hypovolemic shock in 16%, while other types of distributed shock (such as neurogenic shock and anaphylactic shock) accounted for 4% a…”
McCloskey, M. M., Gibson, G. A., Pope, H. E., Giacomino, B. D., Hampton, N. B., Micek, S. T., Kollef, M. H., & Betthauser, K. D. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221095543 · Cited by 10
Haertel, F., Lehmann, T., Heller, T., Fritzenwanger, M., Pfeifer, R., Kretzschmar, D., Otto, S., Bogoviku, J., Westphal, J. G., Bruening, C., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12154893 · Cited by 10
“It has been observed that the administration of dopamine is associated with an increased incidence of arrhythmic events and higher mortality rates among patients with cardiogenic shock [27,28].”
BackgroundZampieri, F. G., Bagshaw, S. M., Njimi, H., Vincent, J., Backer, D. D., SOAP II Investigators, Biston, P., Devriendt, J., Madl, C., Chochrad, D., et al. (2024) · Critical Care · doi:10.1186/s13054-024-05016-9 · Cited by 10
Self-citationThe Role of Antioxidants in Sepsis Management: A Review of Therapeutic Applications
Üstündağ, H. (2023) · Erzurum Technical University · Cited by 10
Management of Cardiogenic Shock in Patients with Acute Myocardial Infarction
Kunkel, K. J., Fuller, B. S., & Basir, M. B. (2021) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2021.03.006 · Cited by 10
Kim, K., Choi, H. S., Chung, S. P., & Kwon, W. Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-5406-8_5 · Cited by 10
Sex-related differences in patients presenting with heart failure–related cardiogenic shock
Sundermeyer, J., Kellner, C., Beer, B. N., Besch, L., Dettling, A., Bertoldi, L. F., Blankenberg, S., Dauw, J., Dindane, Z., Eckner, D., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02392-8 · Cited by 10
Advances in pathogenesis and current therapeutic strategies for cardiorenal syndrome
Du, Y., Li, X., & Liu, B. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.10.003 · Cited by 10
Vasopressors for Hypotensive Shock
Lampard, J. G., & Lang, E. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.08.028 · Cited by 10
Hosseinpour, A., van Steenberghe, M., Bernath, M.-A., Bernardo, S. D., Perez, M., Longchamp, D., Dolci, M., Boegli, Y., Sekarski, N., Orrit, J., et al. (2017) · Congenital Heart Disease · doi:10.1111/chd.12485 · Cited by 10
Adverse Drug Reactions in the Intensive Care Unit
Moore, P. W., & Burkhart, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_33 · Cited by 10
“Several studies demonstrate no advantage of dopamine over norepinephrine, and dopamine is associated with increased rates of arrhythmias and 28-daymortality for patients with cardiogenic and/or septic shock [122, 123].”
BackgroundMain Considerations of Cardiogenic Shock and Its Predictors: Systematic Review
Braile-Sternieri, M. C. V. B., Mustafa, E. M., Ferreira, V. R. R., Sabino, S. B., Sternieri, G. B., de Faria, L. A. B., Sbardellini, B. C., Queiroz, C. O. V., Braile, D. M., & Filho, I. J. Z. (2018) · Cardiology Research · doi:10.14740/cr715w · Cited by 10
“Laboratory tests, such as blood count, renal function, blood glucose, lactate blood gas, coagulogram, CKMB and troponin, and imaging should be requested to evaluate the systemic repercussions of the shock, to identify its probable etiology and comorbidities [21].”
BackgroundCormican, D. S., Sonny, A., Crowley, J., Sheu, R. D., Sun, T., Gibson, C. M., Nuñez-Gil, I. J., & Ramakrishna, H. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.10.062 · Cited by 10
Vasopressor and inotrope treatment for septic shock: An umbrella review of reviews
Einav, S., Helviz, Y., Ippolito, M., & Cortegiani, A. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.05.017 · Cited by 10
- (2011) · Intensivmedizin und Notfallmedizin · doi:10.1007/s00390-011-0284-8 · Cited by 10
Maternal and Perinatal Infection—Bacterial
Duff, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1935-2.00051-x · Cited by 10
Dopamine Versus Norepinephrine for the Treatment of Septic Shock EBEM Commentators
Sandifer, J. P., & Jones, A. E. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.04.012 · Cited by 10
Li, X., Wang, R., Kang, Y. M., Liu, J., Zuo, Y.-X., Zeng, X.-F., & Cheng, G. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/3948795 · Cited by 10
“5% mortality in the control group [24].”
Critical care considerations in the management of acute-on-chronic liver failure
MacDonald, A. J., Olson, J. C., & Karvellas, C. J. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000698 · Cited by 10
“3 mg/kg/min) is recommended as first-line therapy in distributive shock, as it is associated with fewer adverse events [24].”
BackgroundAssociation between vasopressin administration and mortality in patients with cardiogenic shock
Sarma, D., Smith, R. S., Padkins, M. R., Rali, A. S., Vallabhajosyula, S., Khanna, A. K., KASHANI, K. B., Hibbert, B. M., & Jentzer, J. C. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.03.009 · Cited by 9
Miró, Ò., Chioncel, O. D., Mebazaa, A., Sato, N., Butler, J., Davison, B. A., Biegus, J., Pagnesi, M., Ambrosy, A. P., Savarese, G., et al. (2025) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001270 · Cited by 10
Evaluación y manejo de emergencias en el paciente con cirrosis
Velasco, J. A. V.-R., García-Jiménez, E. S., Aldana-Ledesma, J. M., Tapia-Calderón, D. K., Tornel-Avelar, A. I., Lazcano-Becerra, M., Chávez-Ramírez, R. M., Cano-Contreras, A. D., Remes-Troche, J. M., Colunga‐Lozano, L. E., et al. (2022) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2021.11.002 · Cited by 9
“El uso de corticosteroides en sepsis puede resultar en una peque˜na reducción absoluta de la mortalidad.”
BackgroundManagement of Arrhythmias in the Cardiovascular Intensive Care Unit
Klinkhammer, B., & Glotzer, T. V. (2023) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccc.2023.06.003 · Cited by 9
Lawson, C. K., Faine, B. A., Rech, M. A., Childs, C., Brown, C. S., Slocum, G. W., Acquisto, N. M., & Ray, L. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.12.031 · Cited by 9
ICU management of cardiogenic shock before mechanical support
Schaubroeck, H., Roßberg, M., Thiele, H., & Pöss, J. (2024) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001182 · Cited by 9
“For many patients with cardiogenic & randomized controlled DOREMI (Dobutamine Compared to Milrinone in the Treatment of Cardiogenic Shock) trial demonstrated similar hemodynamic effects, outcomes, and safety profiles for dobutamine compared to the phosphodiesterase (PDE)-3-inhibitor milrinone in a…”
Background
Metadata
- Authors
- De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L.
- Affiliations
- Université Libre de Bruxelles (BE)
- Medical University of Vienna (AT)
- Centre hospitalier Etterbeek-Ixelles (BE)
- Erasmus Hospital (BE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 779-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095944485
- Cited by
- 1,940
- References
- 31
- Citations by year
- 2026: 98 · 2025: 107 · 2024: 140 · 2023: 115 · 2022: 125 · 2021: 132 · 2020: 135 · 2019: 138 · 2018: 106 · 2017: 139 · 2016: 99 · 2015: 122 · 2014: 120 · 2013: 96 · 2012: 110
- FWCI
- 83.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
- Keywords
- dopamine, norepinephrine, vasopressors, shock, cardiogenic shock, septic shock, hypovolemic shock, 28-day mortality, cardiac arrhythmias, epinephrine, vasopressin, organ support, adverse events, subgroup analysis, vasopressor weaning
- MeSH terms
- Aged, Arrhythmias, Cardiac, Combined Modality Therapy, Dopamine, Female, Fluid Therapy, Humans, Male, Middle Aged, Norepinephrine, Shock, Vasoconstrictor Agents, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.